Trials / Completed
CompletedNCT02118064
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma
A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 161 (actual)
- Sponsor
- Cancer Advances Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | G17DT-Irinotecan | 500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes. |
Timeline
- Start date
- 2001-03-01
- Primary completion
- 2002-12-01
- First posted
- 2014-04-21
- Last updated
- 2014-04-21
Source: ClinicalTrials.gov record NCT02118064. Inclusion in this directory is not an endorsement.